arXiv:2605.29108v1 Announce Type: new Abstract: Selecting efficient multi-step synthetic routes is a central challenge in organic synthesis, particularly in medicinal and process chemistry, where route choice directly impacts feasibility, cost, and development efficiency. Data-driven assessment systems often oversimplify the multi-objective nature of synthesis design and rely on proxy datasets, such as patent routes, rather than universally grounded criteria. To address this, we introduce an expert-augmented, data-driven scoring framework that integrates machine learning with chemists' domain
The increasing complexity of organic synthesis and the availability of advanced machine learning techniques are converging, necessitating more sophisticated AI tools for chemistry.
This development represents a significant step towards more efficient and reliable drug discovery and materials science, reducing timelines and costs in critical industries.
The process of evaluating synthetic routes will become more robust, integrating expert chemical knowledge directly into AI-driven assessment systems, moving beyond purely data-driven proxies.
- · Pharmaceutical companies
- · Chemical manufacturers
- · AI/ML developers in chemistry
- · Materials science researchers
- · Companies relying solely on traditional synthesis methods
- · Inefficient drug discovery pipelines
Faster and more cost-effective development of new drugs and advanced materials.
Increased competition among pharmaceutical and chemical companies due to accelerated innovation cycles.
Potential for new industries to emerge based on the rapid synthesis of previously unimaginable compounds.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.LG